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naintained a normal TSH during those two to eight 
*se Reactions: Adverse reactions, other than those 
tive of hyperthyroidism because of therapeutic over-
, either initially or during the maintenance period are 
See OVERDOSAGE). 
»instances, allergic skin reactions have been reported 
ytomel (liothyronine sodium, SK&F) Tablets. 
osage: 
and Symptoms—Headache, irritability, nervousness, 
tig, tachycardia, increased bowel motility and men-
irregularities. Angina pectoris or congestive heart 
may be induced or aggravated. Shock may also de-
Massive overdosage may result in symptoms resem-
hyroid storm. Chronic excessive dosage will produce 
ns and symptoms of hyperthyroidism. 
tent of Overdosage—Dosage should be reduced or 
f temporarily discontinued if signs and symptoms of 
jage appear. Treatment may be reinstituted at a 
losage. In normal individuals, normal hypothalamic-
ry-thyroid axis function is restored in six to eight 
after thyroid suppression. 
ent of acute massive thyroid hormone overdosage is 
it reducing gastrointestinal absorption of the drugs 
interacting central and peripheral effects, mainly 
f increased sympathetic activity. Vomiting may be 
I initially if further gastrointestinal absorption can 
bly be prevented and barring contraindications such 
, convulsions, or loss of the gagging reflex. Treatment 
tomatic and supportive. Oxygen may be administered 
tilation maintained. Cardiac glycosides may be indi-
congestive heart failure develops. Measures to con-
*r, hypoglycemia, or fluid loss should be instituted if 
Antiadrenergic agents, particularly propranolol, 
*en used advantageously in the treatment of in-
sympathetic activity. Propranolol may be adminis-
travenously at a dosage of 1 to 3 mg. over a 10-minute 
r orally, 80 to 160 mg./day, especially when no con-
ations exist for its use. 
and Administration: The dosage of thyroid hor-
B determined by the indication and must in every 
individualized according to patient response and 
ry findings. 
hormones are given orally. In acute, emergency 
ns, injectable levothyroxine sodium may be given 
ously when oral administration is not feasible or 
;, as in the treatment of myxedema coma or during 
enteral nutrition j " -stable liothyronine sodium is 
lable from Smith Kline &French Laboratories upon 
under investigational status, for the treatment of 
na coma. Intramuscular administration of these two 
ions is not advisable because of reported poor ab-
tomel (liothyronine sodium, SK&F) Tablets once-
lage is recommended; although liothyronine sodium 
>id cutoff, its metabolic effects persist for a few days 
r
 discontinuance. 
lypothyroidism: Recommended starting dosage is 
. daily. Daily dosage then may be increased by 12.5 
ncg. every one or two weeks. Usual maintenance 
26-75 meg. daily. Smaller doses may be fully effec-
some patients, while dosage of 100 meg. daily may 
lired in others. 
pid onset and dissipation of action of liothyronine 
(T3), as compared with levothyroxine sodium (T4), 
some clinicians to prefer its use in patients who 
>e more susceptible to the untoward effects of thy-
sdication. However, the wide swings in serum T3 
hat follow its administration and the possibility of 
ronounced cardiovascular side effects tend to coun-
nce the stated advantages. 
1 (liothyronine sodium, SK&F) Tablets may be used 
srence to levothyroxine (T4) during radioisotope 
Lg procedures, since induction of hypothyroidism in 
ises is more abrupt and can be of snorter duration, 
also be preferred when impairment of peripheral 
ion of T4 and T3 is suspected. 
ma: Recommended starting dosage is 5 meg. 
his may be increased by 5 to 10 meg. daily every 
wo weeks. When 25 meg. daily is reached, dosage 
*n be increased by 12.5 or 25 meg. every one or two 
Jsual maintenance dose is 50 to 100 meg. daily. 
ma Coma: Myxedema coma is usually precipi-
the hypothyroid patient of long standing by inter-
illness or drugs such as sedatives and anesthetics 
uld be considered a medical emergency. A 'Cyto-
ection Kit for the emergency treatment of myx-
oma is available from Smith Kline &French Labo-
upon request, under investigational status. In-
IS which accompany this kit provide information 
nistration. 
tal Hypothyroidism: Recommended starting 
5 meg. daily, with a 5 meg. increment every three 
ays until the desired response is achieved. Infants 
nths old may require only 20 meg. daily for main-
At one year, 50 meg. daily may be required. 
Above three years, full adult dosage may be necessary (See 
' PRECAUTIONS, Pediatric Use). 
Simple (non-toxic) Goiter: Recommended starting dosage 
is 5 meg. daily. This dosage may be increased by 5 to 10 
meg. daily every one or two weeks. When 25 meg. daily is 
reached, dosage may be increased every week or two by 
12.5 or 25 meg. Usual maintenance dosage is 75 meg. daily. 
In the elderly or in children, therapy should be started with 5 
meg. daily and increased only by 5 meg. increments at the 
recommended intervals. 
When switching a patient to Cytomel (liothyronine sodium, 
SK&F) Tablets from thyroid, L-thyroxine or thyroglobulin, 
discontinue the other medication, initiate 'Cytomel' at a low 
dosage, and increase gradually according to the patient's 
response. When selecting a starting dosage, bear in mind 
that this drug has a rapid onset of action, and that residual 
effects of the other thyroid preparation may persist for the 
first several weeks of therapy. 
Thyroid Suppression Therapy: Administration of thyroid 
hormone in doses higher than those produced physiologi-
cally by the gland results in suppression of the production of 
endogenous hormone. This is the basis for the thyroid sup-
pression test and is used as an aid in the diagnosis of patients 
with signs of mild hyperthyroidism in whom baseline labora-
tory tests appear normal or to demonstrate thyroid gland 
autonomy in patients with Graves' ophthalmopathy. 131I 
uptake is determined before and after the administration of 
the exogenous hormone. A 50 percent or greater suppression 
of uptake indicates a normal thyroid-pituitary axis and thus 
rules out thyroid gland autonomy. 
Cytomel (liothyronine sodium, SK&F) Tablets are given in 
doses of 75-100 meg./day for seven days, and radioactive io-
dine uptake is determined before and after administration of 
the hormone. If thyroid function is under normal control, the 
radioiodine uptake will drop significantly after treatment. 
Cytomel (liothyronine sodium, SK&F) Tablets should be ad-
ministered cautiously to patients in whom there is a strong 
suspicion of thyroid gland autonomy, in view of the fact that 
the exogenous hormone effects will be additive to the endoge-
nous source. 
How Supplied: Cytomel (liothyronine sodium, SK&F) 
tablets: 5 meg. in bottles of 100; 25 meg. in bottles of 100 and 
1000; and 50 meg. in bottles of 100. 
CY:L30 
Shown in Product Identification Section, page 429 
DARBID® TABLETS, 5 mg. B 
[dahr'bid] 
(brand of isopropamide iodide) 
Description: Darbid (brand of isopropamide iodide) is avail-
able as a tablet for oral administration. Each round, pink, 
coated tablet is imprinted SKF and D62 and contains isopro-
pamide iodide equivalent to 5 mg. of isopropamide. Inactive 
ingredients consist of acacia, calcium sulfate, FD&C Red No. 
3, FD&C Yellow No. 6, gelatin, iron oxide, mineral oil, starch, 
stearic acid, sucrose, talc, titanium dioxide and trace 
amounts of other inactive ingredients. 
Chemically, Darbid (isopropamide iodide, SK&F) is (3-carbam-
oyl-3, 3-diphenylpropyl) diisopropylmethyl ammonium io-
dide. 
Actions: Isopropamide iodide is a synthetic anticholinergic 
that produces 10- to 12-hour gastric acid antisecretory effect 
and gastrointestinal antispasmodic response in man. 
Indications: 'Darbid' is effective as adjunctive therapy in 
the treatment of peptic ulcer. 
'DARBID' HAS NOT BEEN SHOWN TO BE EFFECTIVE 
AS SOLE THERAPY IN CONTRIBUTING TO THE HEALr 
ING OF PEPTIC ULCER, DECREASING THE RATE OF 
RECURRENCE OR PREVENTING COMPLICATIONS. 
To be effective, dosage must be titrated to the individual pa-
tient's needs. 
Contraindications: Glaucoma; obstructive uropathy (e.g., 
bladder neck obstruction due to prostatic hypertrophy); ob-
structive disease of the gastrointestinal tract (as in acha*: 
sia, pyloroduodenal stenosis, etc.); obstructive or paralytic 
ileus, intestinal atony of the elderly or debilitated patient; 
unstable cardiovascular status in acute hemorrhage; severe 
ulcerative colitis; toxic megacolon complicating ulcerative 
colitis; myasthenia gravis. 
Warnings: In the presence of a high environmental temper-
ature, heat prostration (fever and heat stroke due to de-
creased sweating) can occur. 
In patients with diarrhea due to incomplete intestinal ob-
struction (especially those with ileostomy or colostomy), 
treatment with Darbid (isopropamide iodide, SK&F) would be 
inappropriate and possibly harmful. 
'Darbid' may produce drowsiness or blurred vision. In this 
event, the patient should be warned not to engage in activi-
ties requiring mental alertness such as operating a motor 
vehicle or other machinery or perform hazardous work while 
taking this drug. 
Usage in Pregnancy: In pregnancy, lactation, and in women 
who may bear children, the potential benefits of the drug 
must be weighed against possible hazards. 
Precautions: Use cautiously in elderly patients. 
Since the iodine in isopropamide iodide may alter PBI test 
results and will suppress I131 uptake, it is suggested that 
therapy be discontinued one week prior to these tests. Also, 
iodine skin rash may^occur rarely. 
Use with caution in ^patients with: 
Autonomic neuropathy. 
Hepatic or renal disease. 
Ulcerative colitis Qarge doses may suppress intestinal motil-
ity to the point of producing paralytic ileus, and the use of 
this drug may precipitate or aggravate the serious complica-
tion of toxic megacolon). 
Hyperthyroidism, coronary heart disease, congestive heart 
failure, cardiac arrhythmia, hypertension and nonobstruct-
ing prostatic hypertrophy. . ' ;• 
Hiatal hernia associated with reflux'esophagitis (anticholin-
ergic drugs may aggravate this condition). -
It should be noted that the use of anticholinergic drugs in the 
treatment of gastric ulcer may produce a delay in gastric 
emptying time (antral stasis) and, thus, complicate therapy. 
Do not rely on the use of the drug in the presence of complica-
tion of biliary tract disease. 
Investigate any tachycardia before giving anticholinergic 
(atropine-like) drugs, since they may increase the heart rate. 
With overdosage, a curare-like action may occur. 
Adverse Reactions: Anticholinergics produce certain phar-
macological effects which may be desirable or undesirable, 
depending upon the individual patient's response. The physi-
cian must delineate these. 
Adverse reactions which have occurred with Darbid (isopro-
pamide iodide, SK&F) include: xerostomia (dry mouth); uri-
nary hesitancy and retention; blurred vision; tachycardia; 
palpitations; mydriasis (dilatation of the pupils); cycloplegia; 
constipation; bloated feeling; nausea; dysphagia; fever; and 
nasal congestion. 
Other adverse reactions possible with anticholinergics in-
clude: increased ocular tension; loss of taste; headaches; ner-
vousness; drowsiness; weakness; dizziness; insomnia; vomit-
ing; impotence; suppression of lactation; severe allergic reac-
tion or drug idiosyncrasies including anaphylaxis; urticaria 
and other dermal manifestations; some degree of mental 
confusion and/or excitement, especially in elderly persons. 
Decreased sweating may occur. It should be noted that ad-
renergic innervation of the eccrine sweat glands on the 
palms and soles makes complete control of sweating impossi-
ble. An end point of complete anhidrosis cannot occur be-
cause large dos _ °f drug would be required, and this would 
produce severe ^ae effects from parasympathetic paralysis. 
Dosage and Administration: Not for use in children un-
der 12. Adults and children over 12—Usual starting dose is 
one 5 mg. tablet b.i.d. (every 12 hours). Patients with severe 
symptoms may require two 5 mg. tablets b.i.d., or more. Dos-
age should be individualized and titrated to the patient's 
need for greatest therapeutic effect. 
Overdosage: Involves the cardiovascular, respiratory, gas-
trointestinal, central and peripheral nervous systems. 
SYMPTOMS—May include dryness of mouth, dysphagia, 
thirst, blurred vision, dilated pupils, photophobia, fever, 
rapid pulse and respiration, disorientation. Expression and 
circulatory collapse may result from severe overdosage. 
TREATMENT—Gastric lavage, repeated several times. 
Respiratory depression should be promptly treated by the 
use of oxygen and stimulants. If marked excitement is pres-
ent, one of the short-acting barbiturates, chloral hydrate, or 
gas anesthesia may be used. Otherwise do not administer 
sedation. Hyperpyrexia may be treated with physical cooling 
measures. Force fluids by mouth or, if necessary, by intrave-
nous administration. 
While pilocarpine or similar drugs are sometimes recom-
mended for the relief of dry mouth, many authorities feel 
that these drugs are not indicated, since they relieve the 
minor peripheral effect but do not influence the more serious 
central effects and, thus, may merely mask signs of drug 
activity. If photophobia occurs, the patient should be kept in 
a darkened room. 
How Supplied: Tablets, 5 mg., in bottles of 50. 
Shown in Product Identification Section, page 429 
DB.-L16 
DEXEDRINE® € 
[dex 'eh-dreen ] 
(brand of dextroamphetamine sulfate) 
SPANSULE® CAPSULES, 
TABLETS and ELIXIR 
Warning: 
AMPHETAMINES HAVE A HIGH POTENTIAL FOR 
ABUSE. THEY SHOULD THUS BE TRIED ONLY IN 
WEIGHT REDUCTION PROGRAMS FOR PATIENTS 
IN WHOM ALTERNATIVE THERAPY HAS BEEN 
INEFFECTIVE. ADMINISTRATION OF AMPHETA-
I MINES FOR PROLONGED PERIODS OF TIME IN | 
Continued on next page 
Always consult Supplement 
* & French—Cont. 
{ LEAD TO DRUG DEPENDENCE AND 
/OIDED PARTICULAR ATTENTION 
PAID TO THE POSSIBILITY OF SUB-
[NING AMPHETAMINES FOR NON 
C USE OR DISTRIBUTION TO OTH 
E DRUGS SHOULD BE PRESCRIBED 
D SPARINGLY 
>xednne (dextroamphetamine sulfate, 
ttro isomer of the compound d,l -amphet-
sympathomimetic amine of the amphet 
»mically, dextroamphetamine is d -alpha 
imine, and is oresent in all forms of 'Dexe-
ral sulfate 
ies 
istamed release capsule is so prepared that 
eleased promptly and the remaining medi 
gradually over a prolonged period 
h brown cap and natural body, contains 
ne sulfate as follows 5mg imprinted SKF 
npnnted SKF and E13,15 mg imprinted 
ctive ingredients consist of acacia, benzyl 
mlfate, cetylpyndinium chloride, FD&C 
Red No 40, FD&C Yellow No 5 (tartra 
H[ No 6 gelatin glyceryl distearate, glyc 
< sodium lauryl sulfate, starch, sucrose, 
uints of other inactive ingredients 
an^je, scored tablet is debossed SKF and 
xtn^amphetamine sulfate, 5 mg Inactive 
of cai^mm sulfate, FD&C Yellow No 5 
ifellow **Jo 6, gelatm, lactose, mineral oil, 
sucrose, <talc and trace amounts of other 
poonful) o-^ f clear, orange-colored, orange-
ains dextroamphetamine sulfate, 5 mg, 
Inactive
 0 ingredients consist of benzoic 
feC Yellovw No 5 (tartrazme), FD&C Yel 
icrose, waiter and wine 
ology .^Amphetamines are non-cate-
lomimeti^ amines with CNS stimulant 
actions include elevations • ystohcand 
ures and 'weak bronchodilator and respi 
tion 
cific e, vidence which clearly establishes 
reby aunphetamines produce mental and 
i children, nor conclusive evidence re-
ffect^ s relate to the condition of the cen 
ise^i in obesity are commonly known as 
toxigenics " It has not been established, 
tion of such drugs m treating obesity is 
e tite suppression Other central nervous 
netabolic effects, may be involved, for 
> instructed in dietary management and 
tic ' drugs lose more weight on the aver 
ed with placebo and diet, as determined 
*rm clinical trials 
tcreased weight loss of drug treated pa 
reated patients is only a fraction of a 
ate of weight loss is greatest m the first 
r both drug and placebo subjects and 
succeeding weeks The origins of the 
»due to the various possible drug effects 
The amount of weight loss associated 
norectic" drug vanes from trial to trial, 
lght loss appears to be related in part to 
the drug prescribed, such as the physi 
1
 population treated, and the diet pre-
Dt permit conclusions as to the relative 
ig and nondrug factors on weight loss 
f obesity is measured in years, whereas 
estricted to a few weeks' duration, thus, 
ug induced weight loss over that of diet 
ered clinically limited 
lphetamine sulfate SK&F) Spansule 
ed to release the active drug substance 
ual fashion than the standard formula 
1 by blood levels The formulation has 
lor in effectiveness over the same dos 
i, noncontrolled release formulations 
3mg of dextroamphetamine sulfate in 
volunteers produced an average peak 
lood level of 33 2 ng /ml The half life 
average urinary recovery was 38% in 
^estion of two 5 mg tablets by healthy 
in average peak dextroamphetamine 
blood level of 29 2 ng /ml at 2 hours post administration 
The average half life was 10 25 hours The average, unnary 
recovery was 45% m 48 hours 
'Spansule' capsule—Ingestion of a 'Spansule' capsule con 
taming 15 mg radiolabeled dextroamphetamine sulfate by 
healthy volunteers produced a peak blood level of radioactiv 
lty, on the average, at 8-10 hours post administration with 
peak urinary recovery seen at 12-24 hours 
Indications and Usage Dexednne (dextroamphetamine 
sulfate, SK&F) is indicated 
1 In Narcolepsy 
2 In Attention Deficit Disorder with Hyperactivity, as an 
integral part of a total treatment program which typically 
includes other remedial measures (psychological, educa 
tional, social) for a stabilizing effect in children with a 
behavioral syndrome characterized by the following group 
of developmentally inappropriate symptoms moderate to 
severe distractibihty, short attention span, hyperactivity, 
emotional lability, and impulsivity The diagnosis of this 
syndrome should not be made with finality when these 
symptoms are only of comparatively recent origin Nonlo-
calizmg (soft) neurological signs, learning disability, and 
abnormal EEG may or may not be present, and a diagnosis 
of central nervous system dysfunction may or may not be 
warranted 
3 In Exogenous Obesity, as a short term (a few weeks) ad 
junct in a regimen of weight reduction based on caloric 
restriction, for patients refractory to alternative therapy, 
e g , repeated diets, group programs, and other drugs The 
limited usefulness of amphetamines (see CLINICAL 
PHARMACOLOGY) should be weighed against possible 
risks inherent in use of the drug, such as those described 
below 
Contraindications Advanced artenosclerosis, sympto-
matic cardiovascular disease, moderate to severe hyperten 
sion, hyperthyroidism, known hypersensitivity or ldiosyn 
crasy to the sympathomimetic amines, glaucoma 
Agitated states 
Patients with a history of drug abuse 
During or withm 14 days following the administration of 
monoamine oxidase inhibitors (hypertensive crises may re-
sult) 
Warning When tolerance to the "anorectic" effect devel 
ops, the recommended dose should not be exceeded in an 
attempt to increase the effect, rather, the drug should be 
discontinued 
Precaut ions 
General Caution is to be exercised in prescribing ampheta 
mine ^ patients with even mild hypertension 
The least amount feasible should be prescribed or dispensed 
at one time in order to minimize the possibility of overdos 
age 
These products contain FD&C Yellow # 5 (tartrazme), which 
may cause allergic type reactions (including bronchial 
asthma) m certain susceptible individuals Although the 
overall incidence of FD&C Yellow # 5 (tartrazme) sensitivity 
m the general population is low, it is frequently seen m pa 
tients who a\so have aspirin hypersensitivity 
Information for Patients Amphetamines may impair the 
ability of the patient to engage m potentially hazardous ac 
tivities such as operating machinery or vehicles, the patient 
should therefore be cautioned accordingly 
Drug Interactions 
Acidifying agents—Gastrointestinal acidifying agents (gua 
nethidme, reserpine, glutamic acid HC1, ascorbic acid, fruit 
juices, etc) lower absorption of amphetamines Unnary 
acidifying agents (ammonium chloride, sodium acid 
phosphate, etc) increase the concentration of the ionized 
species of the amphetamine molecule, thereby increasing 
urinary excretion Both groups of agents lower blood levels 
and efficacy of amphetamines 
Adrenergic blockers—Adrenergic blockers are inhibited by 
amphetamines 
Alkalinizmg agents—Gastrointestinal alkalinizmg agents 
(sodium bicarbonate, etc) increase absorption of ampheta 
mines Urinary alkalinizmg agents (acetazolamide some 
thiazides) increase the concentration of the non ionized spe-
cies of the amphetamine molecule, thereby decreasing un 
nary excretion Both groups of agents increase blood levels 
and therefore potentiate the actions of amphetamines 
Antidepressants, tricyclic—Amphetamines may enhance 
the activity of tricyclic or sympathomimetic agents d 
amphetamine with desipramine or protnptylme and possi 
bly other tricyclics cause striking and sustained increases in 
the concentration of d amphetamine in the bram, cardiovas 
cular effects can be potentiated 
MAO inhibitors—MAOI antidepressants, as well as a metab-
olite of furazolidone, slow amphetamine metabolism This 
slowing potentiates amphetamines, increasing their effect 
on the release of norepinephrine and other monoamines 
from adrenergic nerve endings this can cause headaches 
and other signs of hypertensive crisis A variety of neurologi 
cal toxic effects and malignant hyperpyrexia can occur, 
sometimes with fatal results 
Antihistamines—Amphetamines may counteract the seda 
tive effect of antihistamines 
Antihypertensives—Amphetamines may antagonize ^ e 
hypotensive effects of antihypertensives 
Chlorpromazme—Chlorpromazine blocks dopamine and 
norepinephrine reuptake, thus inhibiting the central stimu 
lant effects of amphetamines, and can be used to treat am 
phetamme poisoning 
Ethosuximide—Amphetamines may delay intestinal absom. 
tion of ethosuximide 
Halopendol—Halopendol blocks dopamine and norepmeph 
rine reuptake, thus inhibiting the central stimulant effects 
of amphetamines 
Lithium carbonate—The antiobesity and stimulatory effects 
of amphetamines may be inhibited by lithium carbonate 4 
Meperidine—Amphetamines potentiate the analgesic effect 
of mependine 
Methenamine therapy—Urinary excretion of ampheta 
mines is increased, and efficacy is reduced, by acidifying 
agents used in methenamine therapy
 i 
Norepinephrine—Amphetamines enhance the adrenergic 
effect of norepinephrine 
Phenobarbital—Amphetamines may delay intestinal ab-
sorption of phenobarbital, co-administration of phenobarbi 
tal may produce a synergistic anticonvulsant action 
Phenytom—Amphetamines may delay intestinal absorption 
of phenytom, co-administration of phenytom may produce a 
synergistic anticonvulsant action 
Propoxyphene—In cases of propoxyphene overdosage, am 
phetamme CNS stimulation is potentiated and fatal convul 
sions can occur 
Veratrum alkaloids—Amphetamines inhibit the hypoten 
sive effect of veratrum alkaloids , 
Drug/Laboratory Test Interactions * ^ 
• Amphetamines can cause a significant elevation m 
plasma corticosteroid levels This increase is greatest in 
the evening 
• Amphetamines may interfere with urinary steroid deter 
mmations 
Carcinogenesis/Mutagenesis Mutagenicity studies and 
long term studies in animals to determine the carcinogenic 
potential of Dexednne (dextroamphetamine sulfate, SK&F^ 
have not been performed 
Pregnancy—Teratogenic Effects Pregnancy Category C 
'Dexednne' has been shown to have embryotoxic and terato-
genic effects when administered to A/Jax mice and C57BL 
mice in doses approximately 41 times the maximum human 
dose Embryotoxic effects were nr seen m New Zealand 
white rabbits given the drug m dose^ / times the human dose 
nor in rats given 12 5 times the maximum human dof-
There are no adequate and well-controlled studies in preg 
nant women 'Dexednne' should be used during pregnancy 
only if the potential benefit justifies the potential risk to the 
fetus t 
Nonteratogenic Effects Infants born to mothers dependent 
on amphetamines have an mcreased risk of premature dehv 
ery and low birth weight Also, these infants may expenence 
symptoms of withdrawal as demonstrated by dysphoria, in 
eluding agitation, and significant lassitude , 
Nursing Mothers It is not known whether this drug is ex-
creted in breast milk, efforts to measure amphetamines in 
breast milk have been unsuccessful Because many drugs are 
excreted in human milk, caution should be exercised when 
Dexednne' is administered to a nursing woman 
Pediatric Use Long term effects of amphetamines in chil 
dren have not been well established 
Amphetamines are not recommended for use as anorectic 
agents in children under 12 years of age, or m children under 
3 years of age with Attention Deficit Disorder with Hyperac 
t m t y described under INDICATIONS AND USAGE 
Clinical experience suggests that in psychotic children, ad 
ministration of amphetamines may exacerbate symptoms of 
behavior disturbance and thought disorder 
Amphetamines have been reported to exacerbate motor and 
phonic tics and Tourette's syndrome Therefore, clinical 
evaluation for tics and Tourette's syndrome in children and 
their families should precede use of stimulant medications 
Data are inadequate to determine wb *Her chronic adminis 
tration of amphetamines may be associated with growth 
inhibition therefore, growth should be monitored during 
treatment 
Drug treatment is not indicated in all cases of Attention Def 
lcit Disorder with Hyperactivity and should be considered 
only in light of the complete history and evaluation of the 
child The decision to prescribe amphetamines should de-
pend on the physician's assessment of the chromcity and 
severity of the child's symptoms and their appropriateness 
for his/her age Prescription should not depend solely on the 
presence of one or more of the behavioral characteristics 
When these symptoms are associated with acute stress reac 
tions treatment with amphetamines is usually not indi 
cated 
Adverse Reactions 
Cardiovascular Palpitations, tachycardia elevation of 
blood pressure 
Central Nervous System Psychotic episodes at recom 
mended doses (rare), overstimulation, restlessness, dizziness, 
insomnia euphoria, dyskinesia, dysphoria, tremor, head 
possible revisions \B v'f-
> exacerbation of motor and phonic tics~and Tourette's 
J01n'estmal ' Dryness of the mouth unpleasant taste, 
hea constipation other gastrointestinal disturbances 
eXia and weight loss may occur as undesirable effects 




cr(ne Impotence, changes in libido 
r Abuse and Dependence Dextroamphetamine sul 
's a Schedule II controlled substance r 
hetammes have been extensively abused Tolerance, 
me psychological dependence and severe social disabil 
ave occurred There are reports of patients who have 
ased the dosage to many times that recommended 
pt cessation following prolonged high dosage admims 
n results in extreme fatigue and mental depression, 
es are also noted on the sleep EEG 
Testations of chronic intoxication with amphetamines 
le severe dermatoses marked insomnia, irritability, 
actiuty, and personality changes The most severe 
estation of chronic intoxication is psychosis often clin 
indistinguishable from schizophrenia This is rare 
)ral amphetamines "" * A 
losage Individual patient response to ampheta 
vanes widely While toxic symptoms occasionally oc 
an idiosyncrasy at doses as low as 2 mg, they are rare 
loses of less than 15 mg , 30 mg can produce severe 
)ns, yet doses of 400 to 500 mg are not necessarily fa 
,, the oral LDso of dextroamphetamine sulfate is 96 8 
I 
TOMS—Manifestations of acute overdosage with am 
nines include restlessness, tremor, hyperreflexia, 
espiration, confusion, assaultiveness, hallucinations, 
states 
e and depression usually follow the central stimula 
vascular effects include arrhythmias, hypertension or 
nbion and circulatory collapse Gastrointestinal 
>ms include nausea vomiting, diarrhea and abdoi 
imps Fatal poisoning is usually preceded by convul 
nd coma 
IMENT—Management of acute amphetamine intoxi 
is largely symptomatic and includes gastric lavage 
lation with a barbiturate Experience with hemodialy 
entoneal dialysis is inadequate to permit recommen 
in this regard Acidification of the urine increases 
tamine excretion If acute, severe hypertension com 
> amphetamine overdosage, administration of intra 
phentolamine (Regitine®, CIBA) has been sug 
However, a gradual drop in blood pressure will usu 
ult when sufficient sedation has been achieved 
oraazme antagonizes the central stimulant effects of 
amines and can be used to treat amphetamine intoxi 
uch of the Spansule' capsule medication is coated for 
release therapy directed at reversing the effects of 
*sted drug and at supporting the patient should be 
ed for as long as overdosage symptoms remain Sa 
hartics are useful for hastening the evacuation of 
hat have not already released medication 
and Administration Regardless of indication, 
amines should be administered at the lowest effec 
ige and dosage should be individually adjusted Late 
doses—particularly with the Spansule' capsule 
hould be avoided because of the resulting insomnia 
Dsy Usual dose 5 to 60 milligrams per day in di 
ses depending on the individual patient response 
3sy seldom occurs m children under 12 years of age 
, when it does Dexednne (ccxtroamphetamine su 
&F) may be used The suggested initial dose for pa 
ed 6-12 is 5 mg daily daily dose may be raised in 
its of 5 mg at weekly intervals until optimal re-
obtained In patients 12 years of age and older start 
ng daily daily dosage may be raised in increments 
at weekly intervals until optimal response is ob-
f bothersome adverse reactions appear (e g msom 
lorexia) dosage should be reduced Spansule cap-
> be used for once-a-day dosage wherever appropn 
tablets or elixir give first dose on awakening addi 
ses (1 or 2) at intervals of 4 to 6 hours 
i Deficit Disorder w i t h Hyperactivity Not recom 
or children under 3 years of age 
n f rom 3 to 5 years of age start w i t h 2 5 mg daily 
or elixir daily dosage may be raised in increments 
at weekly intervals until optimal response is ob-
n 6 years of age and older start with 5 mg once or 
lv daily dosage may be raised in increments of 5 
ekly intervals until optimal response is obtained 
are cases will it be necessary to exceed a total of 40 
is per day 
Product Information 
Witli* tablets or elixir, give first dose on awakening "addi 
tional doses (1 or 2) at intefvals*of 4 to 6 hours ir*jp_s2oq; 
Where possible, drug administration should be interrupted 
occasionally to determine if there is a recurrence of behav j 
loral symptoms sufficient to require continued therapy •**» 
Exogenous Obesity Usual dosage is one 10 or 15 mg 'Span 
sule' capsule daily, taken in the morning, or up to 30 mg 
daily by tablets or elixir, taken in divided doses of 5 to 10 mg 
30 to 60 minutes before meals Not recommended for this use 
in children under 12 years of age i 
How Supplied 
'Spansule' capsules available 5 mg, m bottles of 50,10 mg 
and 15 mg, in bottles of 50 and 500 
Tablets, 5 mg, available in bottles of 100 and 1000 
Elixir, 5 mg /5 ml, available in 16 fl oz (473 ml ) bottles 
Shown m Product Identification Section, page 429 > T 
DXL34 
D I B E N Z Y L I N E ® Capsules & 
[di benz 'eh leen ] 
(brand of phenoxybenzamine hydrochloride) 
Description Each 'Dibenzyline' capsule, with red cap and 
red body, is imprinted SKF and E33 and contains phenoxy 
benzamme hydrochloride, 10 mg Inactive ingredients con 
sist of benzyl alcohol, cetylpyndmmm chloride D&C Red No 
33, FD&C Red No 3, FD&C Yellow No 6, gelatin, lactose, 
sodium lauryl sulfate and trace amounts of other inactive 
ingredients f >• ^ * 
'Dibenzyline' is N-<2-Chloroethyl)-N-{l methyl 2 
phenoxyethyl) benzylamine hydrochloride 
Phenoxybenzamine hydrochloride is a colorless, crystalline 
powder with a molecular weight of 340 3 which melts be-
tween 136* and 141*C It is soluble in water, alcohol and chlo-
roform, insoluble in ether 
Actions Dibenzyline (phenoxybenzamine hydrochloride, 
SK&F) is a long acting adrenergic, a receptor blocking agent 
which can produce and maintain "chemical sympathec 
tomy" by oral administration It increases blood flow to the 
skin, mucosa and abdominal viscera, and lowers both supme 
ande *_ *t blood pressures It has no effect on the parasympa 
thetic &ystem "> 
Indication Pb^^hromoc}*^ na, to control episodes of 
hypertension an ! oweating If tachycardia is excessive, it 
may be necessary to use a beta blocking agent concomi 
tantly 
Contraindications Conditions where a fall in blood pres 
sure may be undesirable 
W a r n i n g 'Dibenzyline' induced alpha adrenergic blockade 
leaves beta adrenergic receptors unopposed Compounds 
tha t st imulate both types of receptors may therefore produce 
an exaggerated hypotensive response and tachycardia 
P recau t i ons Phenoxybenzamine hydrochloride has 
shown in vitro mutagenic act iv i ty in the Ames test and in 
the mouse lymphoma assay it has not shown mutagenic 
act iv i ty in the micronucleus test in mice In rats and mice 
repeated intraperitoneal administrat ion of phenoxybenza 
mine hydrochloride resulted in peritoneal sarcomas Chronic 
oral dosing in rats has produced malignant tumors of the 
gastrointestinal tract ' 
The clinical significance of such test results is not estab-
lished Nevertheless these results should be given consider 
at ion in determining the benefit risk ratio as it applies to the 
individual patient 
Administer w i t h caution in patients w i th marked cerebral or 
coronary arteriosclerosis or renal damage Adrenergic block 
ing effect may aggravate symptoms of respiratory infec-
t ions 
Adverse Reactions Nasal congestion miosis postural hy 
potension tachycardia and inhibition of ejaculation may 
occur rt ru se so-called ' side effects" are actually evidence of 
adrenergic blockade and vary according to the degree of 
blockade Furthermore they tend to decrease as therapy is 
continued Gastrointestinal irritation drowsiness and fa 
tigue have also been reported 
Dosage and Administration The dosage should be ad 
justed to fit the needs of each patient Small initial doses 
should be slowly increased until the desired effect is obtained 
or the side effects from blockade become troublesome After 
each increase the patient should be observed on that level be 
fore instituting another increase The dosage should be car 
ned to a point where symptomatic relief and/or objective 
improvement are obtained but not so high that the side ef 
fects from blockade become troublesome 
Initially 10 mg of Dibenzyline (phenoxybenzamine hydro-
chloride SK&F) twice a day Dosage should be increased every 
other day usually to 20 to 40 mg two or three times a da> 
until an optimal dosage is obtained as judged by blood pres 
sure control 
Overdosage Symptoms—These are largely the result of 
block of the sympathetic nervous system and of the circulat 
ing epinephrine They may include postural hypotension 
resulting in dizziness or fainting tachycardia particularly 
postural vomiting lethargy shock Treatment —When 
consideration"' In^cases of rmld overdosage, recumbent jpo 
tion with legs elevated usually res'tores'cerebral circulatic 
In ' the more severe cases the usual measures to comb 
shock should be instituted Usual pressor agents are not 
fective Epinephrine is contramdicated because it stimulat 
both a and y3 receptors, since a receptors are blocked, the n 
effect of epinephrine administration is vasodilation and 
further drop in blood pressure (epinephrine reversal) 
The patient may have to be kept flat for 24 hours or more 
the case of overdose! as the effect of the drug is"prolonge 
Leg band&ges and an abdominal binder may shorten tl 
period of disability * *'
 iX 
I V infusion of levarterenol bitartrate *v may be used to cor. 
bat severe hypotensive reactions, because it stimulates 
receptors pnmaril} Although Dibenzyline (phenoxybenz 
mine hydrochloride, SK&F) is an a adrenergic blocking agen 
a sufficient dose of levarterenol bitartrate will overcome th 
effect v 
How Supplied Dibenzyline (phenoxybenzamine hydr 
chloride, SK&F) capsules, 10 mg, in bottles of 100 
*Ayailable as Levophed® Bitartrate (brand of levarterent 
bitartrate) from Wmthrop Laboratories 
Shown in Product Identification Section, page 429 
DIL2 
D Y A Z I D E ® Capsules 
[dye uh zide' ] 
('Dyazide' is a product of SK&F Co, Carolina, P R 0063C 
Subsidiary of SmithKline Beckman Corporation 
Philadelphia, Pa) 
Warning 
This fixed combination drug is not indicated for initial 
therapy of edema or hypertension Edema or hyperten 
sion requires therapy titrated to the individual patient 
If the fixed combination represents the dosage so deter 
mined, its use may be more convenient in patient man 
agement The treatment of hypertension and edema i£ 
not static, but must be reevaluated as c o i t i o n s m 
each patient warrant 
Description Each red and v*hite 'Dyazide' capsule con 
tains 50 mg of Dyremum® (brand of triamterene), a potassi 
um-sparing agent, and 25 mg of hydrochlorothiazide 
'Dyremum' is 2, 4, 7 tnamino-6-phenylpteridine 
Hydrochlorothiazide is 6-chloro-3, 4-dihydro-2H 1, 2 ,4 ben 
zothiadiazine-7-sulfonamide 1,1 -dioxide 
At 50*C, triamterene is practically insoluble in water (less 
than 0 1%) It is soluble in formic acid, spanngly soluble in 
methoxyethanol, and very slightly soluble in alcohol 
Hydrochlorothiazide is slightly soluble m water It is soluble 
in dilute ammonia, dilute aqueous sodium hydroxide, and 
dimethylformamide It is sparingly soluble in methanol 
Action 'Dyazide is a diuretic/antihypertensive drug prod 
uct that combines the natriuretic hydrochlorothiazide, and 
the potassium sparing natnuretic, triamterene, each of 
which complements the action of the other The hydrochloro-
thiazide component blocks the reabsorption of sodium and 
chloride ions, and thereby increases the quantity of sodium 
traversing the distal tubule and the volume of water ex 
creted A portion of the additional sodium presented to the 
distal tubule is exchanged there for potassium and hydrogen 
ions With continued use of hydrochlorothiazide and deple-
tion of sodium, compensatory mechanisms tend to increase 
this exchange and may produce excessive loss of potassium, 
hydrogen and chloride ions Hydrochlorothiazide also de-
creases the excretion of calcium and uric acid, may increase 
the excretion of iodide and may reduce g lomerul i filtratiou 
rate The exact mechanism of the antihyperteruT ""<{ effect of 
hydrochlorothiazide is not known 
The triamterene component of Dyazide' exerts its diuretic 
effect on the distal renal tubule to inhibit the reabsorption of 
sodium in exchange for potassium and hydrogen ions Its 
natriuretic activity is limited by the amount of sodium 
reaching its site of action Although it blocks the increase in 
this exchange that is stimulated by mmeralocorticoids 
(chiefly aldosterone) it is not a competitive antagonist of al 
dosterone and its activity can be demonstrated m adrenalec 
tomized rats and patients with Addison s disease As a result 
the dose of triamterene required is not proportionally re-
lated to the level of mmeralocorticoid activity but is dictated 
by the response of the individual patient and the kaliuretic 
effect of concomitantly administered drugs By inhibiting 
the distal tubular exchange mechanism triamterene main 
tains or increases the sodium excretion and reduces the ex 
cess loss of potassium hydrogen and chloride ions induced 
by hydrochlorothiazide As with hydrochlorothiazide 
triamterene may reduce glomerular filtration and renal 
plasma flow Via this mechanism it may reduce uric acid 
excretion although it has no tubular effect on uric acid reab-
sorption or secretion Triamterene does not affect calcium ^ 
organism is not likely to be eradicated from the na-
nx of asymptomatic carriers 
vpplied Capsules, 300 mg (opaque scarlet and cara 
ttles of 30, 60, and 100 Also available, Rimac 
[NH (isoniazid USP) Dual Pack containing 60 Rimac-
psules and 30 INH 300-mg Tablets 
ice 
5r, A W , Kirby, W M M, Sherns, J C, and Turck, 
miotic susceptibility testing by a standardized single 
thod Am J Clin Path 45 493-496, 1966 
C83-8 (Rev 7/83) 
)wn in Product Identification Section, page 408 
IN® hydrochloride G 
in] 
ihenidate hydrochloride USP) 
IIM-SR® G 
ihenidate hydrochloride) 
d release tablets 
tion- Ritalin is a white, odorless, fine crystalline 
solutions of which are acid to litmus It is freely solu-
ater 
Pharmacology: Ritalin is a mild central nervous 
timulant 
e of action in man is not completely understood, but 
>resumably activates the brain stem arousal system 
ex to produce its stimulant effect 
neither specific evidence which clearly establishes 
hanism whereby Ritalin produces its mental and 
al effects in children, nor conclusive evidence re-
how these effects relate to the condition of the cen-
s u s system 
n the SR tablets is more slowly but as extensively 
1 as in the regular tablets Relative bioavailability of 
ablet compared to the Ritalin tablet, measured by 
ary excretion of Ritalin major metabolite (a phenyl 
line acetic acid) was 105% (49-168%) in children 
Vo (85-152%) in adults The time to peak rate in chil 
> 4 7 hours (13-8 2 hours) for the SR tablets and 1 9 
3-4 4 hours) for the tablets An average of 67% of SR 
>se was excreted in children as compared to 86% m 
n Deficit Disorder Narcolepsy (previously known 
nal Brain Dysfunction in Children) Other terms 
ed to describe the behavioral syndromf ^ low in 
yperkmetic Child Syndrome, Minimal Biain Dam-
umal Cerebral Dysfunction, Minor Cerebral Dys-
s indicated as an integral part of a total treatment 
which typically includes other remedial measures 
)gical, educational, social) for a stabilizing effect in 
with a behavioral syndrome characterized by the 
I group of developmental^ inappropriate symp-
loderate-to-severe distractibihty, short attention 
peractivity, emotional lability, and impulsivity The 
s of this syndrome should not be made with finality 
Bse symptoms are only of comparatively recent on 
localizing (soft) neurological signs, learning disabil-
abnormal EEG may or may not be present, and a 
s of central nervous system dysfunction may or may 
arranted 
diagnostic Considerations 
etiology of this syndrome is unknown, and there is 
diagnostic test Adequate diagnosis requires the use 
of medical but of special psychological, educational, 
il resources 
nstics commonly reported include chronic history 
attention span, distractibihty, emotional lability, 
ity, and moderate-to-severe hyperactivity, minor 
ical signs and abnormal EEG Learning may or may 
i paired The diagnosis must be based upon a com 
-ory and evaluation of the child and not solely on the 
of one or more o r *hese characteristics 
atment is not inaicdted for all children with this 
B Stimulants are not intended for use in the child 
bits symptoms secondary to environmental factors 
nmary psychiatric disorders, including psychosis 
ate educational placement is essential and psycho-
ervention is generally necessary When remedial 
> alone are insufficient, the decision to prescribe 
t medication will depend upon the physician's as 
of the chronicity and severity of the child's symp-
ldications' Marked anxiety, tension, and agita 
contraindications to Ritalin, since the drug may 
e these symptoms Ritalin is contramdicated also in 
known to be hypersensitive to the drug, in patients 
coma, and in patients with motor tics or with a fam 
y or diagnosis of Tourette's syndrome 
s Ritalin should not be used in children under six 
ice safety and efficacy in this age group have not 
bhshed 
Sufficient data on safety and efficacy of long term use of Rit-
alin in children are not yet available Although a causal rela-
tionship has not been established, suppression of growth (le, 
weight gain, and/or height) has been reported with the long-
term use of stimulants in children Therefore, patients re-
quiring long term therapy should be carefully monitored 
Ritalin should not be used for severe depression of either 
exogenous or endogenous origin Clinical experience sug-
gests that in psychotic children, administration of Ritalin 
may exacerbate symptoms of behavior disturbance and 
thought disorder 
Ritalin should not be used for the prevention or treatment of 
normal fatigue states 
There is some clinical evidence that Ritalin may lower the 
convulsive threshold in patients with prior history of sei-
zures, with prior EEG abnormalities in absence of seizures, 
and, very rarely, in absence of history of seizures and no 
prior EEG evidence of seizures Safe concomitant use of anti 
convulsants and Ritalin has not been established In the 
presence of seizures, the drug should be discontinued 
Use cautiously in patients with hypertension Blood pressure 
should be monitored at appropriate intervals in all patients 
taking Ritalin, especially those with hypertension 
Symptoms of visual disturbances have been encountered in 
rare cases Difficulties with accommodation and blurring of 
vision have been reported 
Drug Interactions 
Ritalin may decrease the hypotensive effect of guanethidine 
Use cautiously with pressor agents and MAO inhibitors 
Human pharmacologic studies have shown that Ritalin may 
inhibit the metabolism of coumann anticoagulants, anticon 
vulsants (phenobarbital, diphenylhydantom, primidone), 
phenylbutazone, and tricyclic antidepressants (lmipramine, 
desipramme) Downward dosage adjustments of these drugs 
may be required when given concomitantly with Ritalin 
Usage in Pregnancy 
Adequate animal reproduction studies to establish safe use 
of Ritalin during pregnancy have not been conducted There-
fore, until more information is available, Ritalin should not 
be prescribed for women of childbearmg age unless, in the 
opinion of the physician, the potential benefits outweigh the 
possible risks 
Drug Dependence 
Ritalin should be given cautiously to emotionally unsta 
ble patients, such as those with a history of drug depen 
dence or alcoholism, because such patients may in 
crease dosage on their own initiative 
Chronically abusive use can lead to marked tolerance 
and psychic dependence with varying degrees of abnor 
mal behavior Frank psychotic episodes can occur, espe 
cially with parenteral abuse Careful supervision is re-
quired during drug withdrawal, since severe depression 
as well as the effects of chronic overactivity can be un 
masked Long term follow up may be required because 
of the patient's basic personality disturbances 
Precautions: Patients with an element of agitation may 
react adversely, discontinue therapy if necessary 
Periodic CBC, differential, and platelet counts are advised 
during prolonged therapy 
Drug treatment is not indicated in all cases of this behavioral 
syndrome and should be considered only in light of the com 
plete history and evaluation of the child The decision to pre-
scribe Ritalin should depend on the physician's assessment 
of the chronicity and severity of the child's symptoms and 
their appropriateness for his/her age Prescription should 
not depend solely on the presence of one or more of the be 
havioral characteristics 
When these symptoms are associated with acute stress reac 
tions, treatment with Ritalin is usually not indicated 
Long term effects of Ritalin in children have not been well 
established 
Adverse Reactions* Nervousness and insomnia are the 
most common adverse reactions but are usually controlled 
by reducing dosage and omitting the drug in the afternoon or 
evening Other reactions include hypersensitivity (including 
skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, 
erythema multiforme with histopathological findings of 
necrotizing vasculitis, and thrombocytopenic purpura), ano-
rexia, nausea, dizziness, palpitations, headache, dyskinesia, 
drowsiness, blood pressure and pulse changes, both up and 
down, tachycardia, angina, cardiac arrhythmia, abdominal 
pain, weight loss during prolonged therapy There have 
been rare reports of Tourette's syndrome Toxic psychosis 
has been reported Although a definite causal relationship 
has not been established, the following have been reported in 
patients taking this drug leukopenia and/or anemia, a few 
instances of scalp hair loss 
In children, loss of appetite, abdominal pain, weight loss 
during prolonged therapy, insomnia, and tachycardia may 
occur more frequently, however, any of the other adverse 
reactions listed above may also occur 
Dosage and Administration Dosage should be individu 
ahzed according to the needs and responses of the patient 
Adults 
Tablets Administer m divided doses 2 or 3 times daily, 
preferably 30 to 45 minutes before meals Average dosage is 
20 to 30 mg daily Some patients may require 40 to 60 mg 
daily In others, 10 to 15 mg daily will be adequate Patients 
who are unable to sleep if medication is taken late in the day 
should take the last dose before 6 p m 
SR Tablets Ritalin SR Tablets have a duration of action of 
approximately 8 hours Therefore, Ritalin SR tablets may be 
used m place of Ritalin tablets when the 8 hour dosage of 
Ritalin SR corresponds to the titrated 8 hour dosage of Rita-
lin 
Children (6 years and over) 
Ritalin should be initiated in small doses, with gradual 
weekly increments Daily dosage above 60 mg is not recom-
mended 
If improvement is not observed after appropriate dosage 
adjustments over a one-month period, the drug should be 
discontinued 
Tablets Start with 5 mg twice daily (before breakfast and 
lunch) with gradual increments of 5 to 10 mg weekly 
SR Tablets Ritalin SR tablets have a duration of action of 
approximately 8 hours Therefore, Ritalin SR tablets may be 
used m place of Ritalin tablets when the 8 hour dosage of 
Ritalin SR corresponds to the titrated 8 hour dosage of Rita-
lin 
If paradoxical aggravation of symptoms or other adverse 
effects occur, reduce dosage, or, unnecessary, discontinue the 
drug 
Ritalin should be periodically discontinued to assess the 
child's condition Improvement may be sustained when the 
drug is either temporarily or permanently discontinued 
Drug treatment should not and need not be indefinite and 
usually may be discontinued after puberty 
Overdosage Signs and symptoms of acute overdosage, 
resulting principally from overstimulation of the central 
nervous system and from excessive sympathomimetic ef-
fects, may include the following- vomiting, agitation, trem-
ors, hyperreflexia, muscle twitching, convulsions (may be 
followed by coma), euphoria, confusion, hallucinations, delir-
ium, sweating, flushing, headache, hyperpyrexia, tachycar-
dia, palpitations v-irdiac arrhythmias, hypertension, mydri-
asis, and dryness of mucous membrane*1 
Treatment consists of appropriate suppv * /e measures The 
patient must be protected against self injury and against 
external stimuli that would aggravate overstimulation al-
ready present If signs and symptoms are not too severe and 
the patient is conscious, gastric contents may be evacuated 
by induction of emesis or gastnc lavage In the presence of 
severe intoxication, use a carefully titrated dosage of a short 
acting barbiturate before performing gastric lavage 
Intensive care must be provided to maintain adequate circu-
lation and respiratory exchange, external cooling proce-
dures may be required for hyperpyrexia 
Efficacy of peritoneal dialysis or extracorporeal hemodialy-
sis for Ritalin overdosage has not been established 
How Supplied 
Tablets 20 mg—round, pale yellow, scored (imprinted CIBA 
34) 
Bottles of 100 NDC 0083-0034 30 
Bottles of 1000 NDC 0083-0034-40 
Tablets 10 mg —round, pale green, scored (imprinted CIBA 
3) 
Bottles of 100 NDC 0083-0003 30 
Bottles of 500 NDC 0083-0003-35 
Bottles of 1000 NDC 0083-0003-40 
Accu Pak® Unit Dose (blister pack) 
Box of 100 (strips of 10) NDC 0083-0003-32 
Tablets 5 mg—r™'nd, yellow (imprinted CIBA 7) 
Bottles of 100 NDC 0083-0007-30 
Bottles of 500 NDC 0083-0007-35 
Bottles of 1000 NDC 0083-0007-40 
SR Tablets 20 mg—round, white, coated (imprinted CIBA 
16) 
Bottles of 100 NDC 0083-0016-30 
Note SR Tablets are color additive free 
Do not store above 86°F (30°C) Protect from moisture 
Dispense in tight, light resistant container (USP) 
C84-29 (Rev 6/84) 
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Continued on next page 
The full prescribing information for each CIBA drug is 
contained herein and is that in effect as of September 1, 
1985 
